MPM Bioimpact LLC Has $808,000 Stock Holdings in Repare Therapeutics Inc. $RPTX

Key Points

• MPM Bioimpact LLC has reduced its stake in Repare Therapeutics Inc. by 33.4%, now holding 819,924 shares valued at $808,000.
• Other institutional investors have increased their holdings in Repare Therapeutics, with significant boosts from Millennium Management and JPMorgan Chase during the 4th quarter.
• The stock received a ratings upgrade from a "sell" to a "hold" by Wall Street analysts, with an average target price of $4.50 and a current trading price of $1.67.

MPM Bioimpact LLC cut its position in shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 33.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 819,924 shares of the company's stock after selling 411,230 shares during the period. MPM Bioimpact LLC owned 1.91% of Repare Therapeutics worth $808,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of RPTX. Millennium Management LLC boosted its holdings in shares of Repare Therapeutics by 65.5% during the 4th quarter. Millennium Management LLC now owns 170,959 shares of the company's stock worth $224,000 after buying an additional 67,638 shares during the period. Stifel Financial Corp boosted its holdings in shares of Repare Therapeutics by 73.1% during the 4th quarter. Stifel Financial Corp now owns 89,500 shares of the company's stock worth $117,000 after buying an additional 37,800 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Repare Therapeutics by 204.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock worth $45,000 after buying an additional 23,127 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Repare Therapeutics by 2,144,950.0% during the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock worth $112,000 after buying an additional 85,798 shares during the period. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Repare Therapeutics by 100.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company's stock worth $197,000 after buying an additional 100,000 shares during the period. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Repare Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $4.50.

Repare Therapeutics Stock Up 0.6%

NASDAQ RPTX opened at $1.67 on Tuesday. The company has a market capitalization of $71.74 million, a P/E ratio of -0.65 and a beta of 0.94. Repare Therapeutics Inc. has a 12-month low of $0.89 and a 12-month high of $4.07. The firm has a 50-day moving average price of $1.52 and a two-hundred day moving average price of $1.34.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.17. The business had revenue of $0.25 million during the quarter, compared to the consensus estimate of $2.50 million. Equities analysts expect that Repare Therapeutics Inc. will post -2.04 EPS for the current year.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.

Want to see what other hedge funds are holding RPTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.